First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Intellia Therapeutics, Inc. (NTLA): the developments shaping its investment case

    Follow the evidence affecting Intellia Therapeutics, Inc.'s demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Intellia Therapeutics, Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-09 · 2 reports
    CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
    Channel: Indirect positive sentiment for gene editing technology and platform validation. Potential for increased investor interest in the broader gene editing space.
    Bullish· 3-12m
    2026-09-09
    CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M
    Channel: Positive sentiment spillover for gene editing technology and platform validation
    Bullish· 3-12m
    2026-09-12
    Cellectis Schedules September 14 Business and CAR T Pipeline Update
    Channel: Second-order effect through sector sentiment. Cellectis's update on gene editing and CAR T development could influence investor perception of the broader gene editing and cell therapy space.
    watch· 1-5d

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-06-15revenueBullishPositive Phase 3 HAELO trial results for lonvo-z and initiated rolling BLA submission support potential U.S. launch in 1H 2027.
    2026-06-15revenueBullishPositive Phase 3 HAELO trial results for lonvo-z and initiated rolling BLA submission support future commercial launch in 2027.

    Event impact log

    5 events mapped to NTLA since 2026-09-09. Evidence through 2026-09-12.

    DateEventChannelDirectionHorizonImpact
    2026-09-12Cellectis Schedules September 14 Business and CAR T Pipeline UpdateSecond-order effect through sector sentiment. Cellectis's update on gene editing and CAR T development could influence investor perception of the broader gene editing and cell therapy space.watch1-5d0.30
    2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales JumpIndirect positive sentiment for gene editing technology and platform validation. Potential for increased investor interest in the broader gene editing space.Bullish3-12m0.40
    2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MPositive read-through for the broader CRISPR gene editing platform and validation of the technology's commercial viability.Bullish3-12m0.30
    2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy CasgevyPositive sentiment spillover for CRISPR-based gene editing companies, potentially increasing investor confidence in the technology platform.Bullish1-3m0.30
    2026-09-09CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76MPositive sentiment spillover for gene editing technology and platform validationBullish3-12m0.40

    Continue this research

    Build your Intellia Therapeutics, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the NTLA entity page →

    Research Intellia Therapeutics, Inc. · $399/mo